The AI drug revolution has the potential to improve clinical successes and human health, but not if it is limited to drug and target discovery in a human-agnostic manner. Scientists should leverage AI to measure human responses to therapeutic treatments during the preclinical stages of drug development. This requires us to incorporate functional human data, including its inherent variability, into preclinical research and validation studies while maintaining scientific reasoning throughout AI model training and analysis.
